AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 83 filers reported holding AMYLYX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $447,057 | -89.2% | 24,416 | -87.3% | 0.00% | -100.0% |
| Q2 2023 | $4,133,049 | +349.8% | 191,611 | +511.8% | 0.00% | +100.0% |
| Q1 2023 | $918,929 | +13.2% | 31,320 | +42.6% | 0.00% | – |
| Q4 2022 | $811,459 | +92.3% | 21,961 | +46.6% | 0.00% | – |
| Q3 2022 | $422,000 | +368.9% | 14,984 | +219.4% | 0.00% | – |
| Q2 2022 | $90,000 | +30.4% | 4,692 | -12.3% | 0.00% | – |
| Q1 2022 | $69,000 | – | 5,349 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
| Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
| Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
| Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
| Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
| Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
| Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
| Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
| Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |